Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cassava Sciences Inc SAVA

Healthcare Biotechnology
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.


NDAQ:SAVA - Post by User

Cassava Sciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by PowerOfTheSunon Aug 29, 2021 12:15pm
280 Views
Post# 33779495

Phase II clinical trial program of the Hemostemix

Phase II clinical trial program of the Hemostemix

Phase II clinical trial program of the Hemostemix blood-derived. 

 

Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)
 

Thomas went on to say that Hemostemix is in the process of completing the source document verification. With about 60% of source documents verified, Thomas said that they expect the source document verification to be complete within the year.

 

https://youtu.be/nQY9SVmCcoU

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities